Phase I results ‘less likely to be published’
The issue of transparency in clinical research has raised its head again with a new study suggesting the results of Phase I trials are less likely to be published compared to other types of studies.
Archives for February 23, 2009
Patheon says JLL’s valuation is “opportunistic”
Patheon says the $183m (€142m) buy-out proposal by private equity group JLL Patheon Holdings is “opportunistic” and designed to take advantage of the recent stock-market related fluctuation in its valuation.
Multinational deals set to continue in Indian pharma
The Indian pharmaceutical and biotech sectors may see more M&A activity this year with rumours that GSK, Sanofi Aventis and Merck KGaA are on the look out for potential deals.
Genentech warns board could turn hostile
As the battle for Genentech continues, the US biotech has warned its shareholders that Roche may “seek to influence our business in a manner that is contrary to our goals or strategies”.
IRB failings compromise trial safety and validity; OHRP
Numerous members of IRBs have conflicts of interest, lack the necessary expertise and fail to follow HHS regulations, according to the OHRP.
SGD launches vials to capture lyophilisation boom
SGD launched its new lyophilisation vials at Pharmapack 2009, which Vincent Langlade, Marketing Director Pharmaceuticals, explained were well suited to capture the growing market.